ITM Medical Isotopes GmbH

What ITM Medical Isotopes GmbH does

ITM Isotope Technologies Munich SE (formerly ITM Medical Isotopes GmbH) is a privately held radiopharmaceutical company headquartered in Garching, Bavaria, Germany, founded in 2006 and operating for over 20 years. The company develops, manufactures, and globally supplies targeted diagnostic and therapeutic radiopharmaceuticals for precision oncology, with a portfolio that combines medical radioisotope production (Lutetium-177 and Actinium-225) with a proprietary pipeline of targeted radiopharmaceutical candidates — ITM-11 (177Lu-edotreotide) for neuroendocrine tumors (GEP-NETs), ITM-31 for glioblastoma, and ITM-22 for prostate cancer. Its lead asset ITM-11 reached a major clinical inflection in July 2026 with the publication of Phase 3 COMPETE trial primary results versus Everolimus in The Lancet, while ITM-31 has produced preliminary Phase 1 data in collaboration with Helmholtz Munich and the University of Münster.

The company's business model combines two revenue layers: a contract-based supply business selling short half-life radioisotopes directly to hospitals, oncology centers, and clinical trial sites worldwide (with a U.S. subsidiary, ITM U.S., supporting North American distribution), and a future therapeutic-product layer contingent on regulatory approval of its pipeline candidates. Pricing is not publicly disclosed and is negotiated per contract with healthcare buyers, consistent with radiopharmaceutical industry practice. The customer base is fragmented across many oncology providers but is concentrated in a relatively small population of nuclear-medicine-capable institutions that can handle therapeutic radioisotopes.

Strategically, ITM is investing in supply-chain resilience (notably the 2026 Actineer partnership for sustainable Radium-226 recycling to underpin Actinium-225 supply), academic co-development relationships to advance early-stage pipeline assets, and global commercial channels (SNMMI and EANM conference presence, peer-reviewed publication strategy, dedicated careers infrastructure). The company is currently pre-launch for its lead therapeutic and is scaling toward first commercial product revenue while expanding its isotope and pipeline footprint.

Name

ITM Medical Isotopes GmbH

Legal name

ITM Isotope Technologies Munich SE

Website

https://itg-garching.de

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

ITM Isotope Technologies Munich SE is a privately held German radiopharmaceutical company that develops and globally supplies targeted alpha- and beta-emitting radioisotope therapies (Lutetium-177, Actinium-225) and a proprietary pipeline (ITM-11, ITM-31, ITM-22) for oncology hospitals and clinical trial sites.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

Keywords

• Targeted radiopharmaceutical therapy
• Medical radioisotope production
• Precision oncology therapeutics
• Lutetium-177 supply
• Actinium-225 production

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Supply Chain, Operations, Personnel, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

ITM Isotope Technologies Munich SE develops, manufactures, and globally supplies targeted therapeutic and diagnostic radiopharmaceuticals and medical radioisotopes for precision oncology. The company produces the medical radioisotopes Lutetium-177 (beta emitter) and Actinium-225 (alpha emitter) and operates a proprietary pipeline of targeted radiopharmaceutical candidates including ITM-11 (177Lu-edotreotide) for neuroendocrine tumors (GEP-NETs), ITM-31 for glioblastoma, and ITM-22 for prostate cancer, distributed directly to hospitals, oncology centers, and clinical trial sites.

Product overview

ITM Isotope Technologies Munich SE operates as a radiopharmaceutical company with a portfolio of targeted diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes. The product offering consists of a pipeline of proprietary radiopharmaceutical candidates (ITM-11 for neuroendocrine tumors, ITM-31 for glioblastoma, ITM-22 for prostate cancer) alongside commercial radioisotope products including Lutetium-177 and Actinium-225. The company provides global supply of radioisotopes and leverages radioisotope leadership to build a precision oncology pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• ITM-11 (177Lu-edotreotide) ITM's lead targeted radiopharmaceutical for neuroendocrine tumors (GEP-NETs), based on Lutetium-177. Completed the Phase 3 COMPETE Trial against Everolimus in advanced GEP-NETs, with primary results published in The Lancet. Intended for oncology centers treating gastroenteropancreatic neuroendocrine tumors.
• ITM-31 Targeted radiopharmaceutical candidate for the treatment of glioblastoma, currently in Phase 1 clinical development in collaboration with Helmholtz Munich and the University of Münster. Updated preliminary Phase 1 data were announced.
• ITM-22 Targeted radiopharmaceutical candidate in development for prostate cancer treatment. Part of ITM's precision oncology pipeline.
• Lutetium-177 Medical radioisotope (beta emitter) supplied globally by ITM for use in targeted radiopharmaceutical therapies and diagnostics for cancer treatment. Used as the active radioisotope in ITM-11 (177Lu-edotreotide) and supplied to other radiopharmaceutical developers and healthcare providers.
• Actinium-225 Medical radioisotope (alpha emitter) supplied by ITM for targeted alpha therapy in cancer treatment. Production capacity advanced through sustainable Radium-226 recycling via the Actineer partnership to enable commercial-scale global supply.

Quantifiable outcome

• Phase 3 COMPETE trial comparing 177Lu-edotreotide (ITM-11) vs. Everolimus in advanced GEP-NETs published in The Lancet

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• ActineercoreStrategic or Co-development Partner · 14 July 2026Partnership focused on sustainable radium-226 recycling to advance reliable commercial-scale production of Actinium-225 for global radiopharmaceutical programs. Actineer achieved sustainable Radium-226 recycling technology, which is critical for Actinium-225 supply chain reliability.
• Helmholtz MunichcoreStrategic or Co-development Partner · 29 June 2026Collaboration on ITM-31 for glioblastoma treatment, with updated preliminary Phase 1 clinical data announced. Joint development of targeted radiopharmaceutical therapy for glioblastoma patients.
• University of MünstercoreStrategic or Co-development Partner · 29 June 2026Collaboration on ITM-31 for glioblastoma treatment alongside Helmholtz Munich, contributing clinical research expertise and Phase 1 patient data for the glioblastoma program.

Scale indicators1 record

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Novartis: Novartis owns Lutathera (177Lu-dotatate) and Pluvicto (177Lu-PSMA-617), the leading approved radioligand therapies directly competing with ITM-11 in GEP-NETs and adjacent prostate cancer indications. It is the dominant commercial incumbent in ITM's primary therapeutic space.
• GE HealthCare: GE HealthCare has a substantial radiopharma and molecular imaging franchise (including its Star PET radiotracer business and partnerships on Lu-177). It is a broad incumbent competing across both imaging agents and therapeutic isotopes relevant to ITM's portfolio.
• Siemens Healthineers: Siemens Healthineers owns PETNET Solutions, one of the largest PET radiopharmaceutical distribution networks, and is expanding into Lu-177 production. It competes as a broad incumbent in isotope supply and nuclear medicine infrastructure.
• Bayer: Bayer operates in radiopharmaceuticals via Xofigo (Ra-223) and Curium partnership, with broad oncology and isotope supply exposure. It competes for alpha/beta therapy mindshare and medical isotope supply contracts relevant to ITM's pipeline.

Direct peers

• Telix Pharmaceuticals: Telix develops and commercializes targeted radiopharmaceuticals (Illuccix for PSMA imaging, TLX591/592 for therapy), making it a close therapeutic and imaging peer. Both companies target precision oncology with Lu-177 and alpha-emitter programs in overlapping indications.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with products including PNT2003 (177Lu-PSMA) and diagnostic imaging agents. It competes directly with ITM on both therapeutic radioligands and diagnostic radioisotope supply to the oncology market.
• Curium Pharma: Curium is a global nuclear medicine company producing diagnostic and therapeutic radiopharmaceuticals, including Lu-177 supply to third-party developers. It is a direct peer in the isotope supply and radiopharma manufacturing business.
• Bracco Imaging: Bracco is a global diagnostic imaging company with radiopharmaceutical and contrast agent offerings. It is comparable to ITM in the medical isotope and imaging/radiopharma space, though more focused on diagnostics than targeted therapy.

Emerging players

• Fusion Pharmaceuticals: Fusion (now part of AstraZeneca) developed targeted alpha therapies using Ac-225, directly overlapping ITM's alpha-emitter pipeline. It represents the next-generation Ac-225 platform competitor and validates the strategic relevance of ITM's isotope strategy.
• POINT Biopharma: POINT Biopharma (acquired by Eli Lilly) develops Lu-177-based radioligand therapies (e.g., PNT2002 for GEP-NETs) — a direct competing program to ITM-11 — and is expanding internal isotope manufacturing capacity, mirroring ITM's vertical-integration thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/itm-medical-isotopes-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ITM Medical Isotopes GmbH